Characterisation of a novel matrix metalloproteinase inhibitor on pancreatic adenocarcinoma cells in vitro and in an orthotopic pancreatic cancer model in vivo

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 273-282

  Kapischke, Matthias ^a,b,d   Fischer, Tim ^b   Tiessen, Katrin ^c   Tschesche, Harald ^b   Bruch, Hans Peter ^a   Kalthoff, Holger ^c   Kruse, Marie Luise ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b BIELEFELD UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Martin Luther Hospital   (Germany)

Author keywords

Matrix metalloproteinases; Mouse model; Pancreatic cancer; Synthetic inhibitor

Indexed keywords

2 (4 BUTYLSULFONYLPHENYL) 3,5 DIOXO 2,3,4,5 TETRAHYDRO 1,2,4 TRIAZIN 6 CARBONITRIL; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TRIAZIN 17 2; TRIAZINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER SIZE; CELL FREE SYSTEM; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SINGLE DRUG DOSE; XENOGRAFT;

EID: 38749137686     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.273     Document Type: Article

References (50)

1. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167, 2002.
2. Roberti A, La Sala D and Cinti C: Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol 207: 571-581, 2006.
3. Kurzeder C, Sauer G and Deissler H: Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Curr Cancer Drug Targets 6: 207-227, 2006.
4. Hooijberg JH, De Vries NA, Kaspers GJ, et al: Multidrug resistance proteins and folate supplementation: therapeutic implications for antifolates and other classes of drugs in cancer treatment. Cancer Chemother Pharmacol 58: 1-12, 2006.
5. Choti MA: Adjuvant therapy for pancreatic cancer - the debate continues. N Engl J Med 350: 1249-1251, 2004.
6. Huang ZQ, Buchsbaum DJ, Raisch KP, et al: Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody. J Surg Res 111: 274-283, 2003.
7. Bramhall SR: Novel non-operative treatment and treatment strategies in pancreatic cancer. Expert Opin Investig Drugs 9: 1179-1195, 2000.
8. Lah TT, Duran Alonso MB and van Noorden CJ: Antiprotease therapy in cancer: hot or not? Expert Opin Biol Ther 6: 257-279, 2006.
9. Hooper NM: Families of zinc metalloproteases. FEBS Lett 354: 1-6, 1994.
10. Bode W, Fernandez-Catalan C, Tschesche H, et al: Structural properties of matrix metalloproteinases. Cell Mol Life Sci 55: 639-652, 1999.
11. Schroeder J, Wenzel H and Tschesche H: 3D-structure and drug design. In: Proteases and their Inhibitors in Cancer Metastasis. Foidart JM and Muschels RJ (eds). Kluewer Academic Publishers, Dordrecht, pp 127-150, 2002.
12. Farrow B, Sugiyama Y, Chen A, et al: Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 239: 763-769, 2004.
13. Kalembeyi I, Inada H, Nishiura R, et al: Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor betal. Int J Cancer 105: 53-60, 2003.
14. Durkin AJ, Bloomston PM, Rosemurgy AS, et al: Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 186: 431-436, 2003.
15. Birkedal-Hansen H, Moore WG, Bodden MK, et al: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250, 1993.
16. Liotta LA and Stetler-Stevenson WG: Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51: 5054-5059, 1991.
17. Liotta LA, Tryggvason K, Garbisa S, et al: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980.
18. Curran S and Murray GI: Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 189: 300-308, 1999.
19. Nelson AR, Fingleton B, Rothenberg ML, et al: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
20. Beckett R and Whittaker M: Matrix metalloproteinase inhibitors. Exp Opin Ther Patents 8: 259-282, 1998.
21. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anticancer agents. Adv Enzyme Regul 35: 293-301, 1995.
22. Alves F, Borchers U, Padge B, et al: Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. Cancer Lett 165: 161-170, 2001.
23. Lin SW, Lee MT, Ke FC, et al: TGFbetal stimulates the secretion of matrix metalloproteinase 2 (MMF2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103. Clin Exp Metastasis 18: 493-499, 2000.
24. Chantrain CF, Shimada H, Jodele S, et al: Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 64: 1675-1686, 2004.
25. Yamashita T, Fujii M, Tomita T, et al: The inhibitory effect of matrix metalloproteinase inhibitor ONO-4817 on lymph node metastasis in tongue carcinoma. Anticancer Res 23: 2297-2302, 2003.
26. Zucker S, Cao J and Chen WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19: 6642-6650, 2000.
27. Cheng Y and Prusoff WH: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108, 1973.
28. Sipos B, Moser S, Kalthoff H, et al: A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 442: 444-452, 2003.
29. Kapischke M, Prinz K, Tepel J, et al: Precoating of alloplastic materials with living human fibroblasts - a feasibility study. Surg Endosc 19: 791-797, 2005.
30. Casey RC, Koch KA, Oegema TR Jr, et al: Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clin Exp Metastasis 20: 343-356, 2003.
31. Tepel J, Kruse ML, March C, et al: Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 28: 1-12, 2004.
32. Tepel J, Kruse ML, Kapischke M, et al: Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model. Pancreatology 6: 240-247, 2006.
33. Knauper V, Osthues A, De Clerck YA, et al: Fragmentation of human polymorphonuclear-leucocyte collagenase. Biochem J 291: 847-854, 1993.
34. Schnierer S, Kleine T, Gote T, et al: The recombinant catalytic domain of human neutrophil collagenase lacks type I collagen substrate specificity. Biochem Biophys Res Commun 191: 319-326, 1993.
35. Muthing J, Unland F, Heitmann D, et al: Different binding capacities of influenza A and Sendai viruses to gangliosides from human granulocytes. Glycoconj J 10: 120-126, 1993.
36. Jackel H and Stamm H: Molecular complexes, 9. Arene complexes of fervenulin, an antibiotic structurally related to caffeine. Formation constants and complex topologies determined by the refined 1H-NMR shift method. Arch Pharm 321: 213-219, 1988.
37. Taylor EC and Sowinski F: Synthesis of the pyrimido [5,4-e]-as-triazine antibiotics fervenulin and 2-methylfevenulone. J Org Chem 40: 2321-2329, 1975.
38. El-Gendy Z, Morsy JM, Allimony HA, et al: Synthesis of heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anticancer drugs, part III. Pharmazie 56: 376-383, 2001.
39. Abdel-Rahman RM: Chemistry of uncondensed 1,2,4-triazines, Part IV. Synthesis and chemistry of bioactive 3-amino-l,2,4-triazines and related compounds - an overview. Pharmazie 56: 275-286, 2001.
40. Abdel-Rahman RM: Role of uncondensed 1,2,4-triazine compounds and related heterobicyclic systems as therapeutic agents - a review. Pharmazie 56: 18-22, 2001.
41. Abdel-Rahman RM, Morsy JM, el-Edfawy S, et al: Synthesis of some new heterobicyclic nitrogen systems bearing the 1,2,4-triazine moiety as anti-HIV and anti-cancer drugs, Part II. Pharmazie 54: 667-671, 1999.
42. Dow RL, Schneider SR, Paight ES, et al: Discovery of a novel series of 6-azauracil-based thyroid hormone receptor ligands: potent, TR beta subtype-selective thyromimetics. Bioorg Med Chem Lett 13: 379-382, 2003.
43. Van Wauwe J, Aerts F, Cools M, et al: Identification of R146225 as a novel, orally active inhibitor of interleukin-5 biosynthesis. J Pharmacol Exp Ther 295: 655-661, 2000.
44. Overall CM and Kleifeld O: Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94: 941-946, 2006.
45. Overall CM and Lopez-Otin C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2: 657-672, 2002.
46. Manzetti S, McCulloch DR, Herington AC, et al: Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10. J Comput Aided Mol Des 17: 551-565, 2003.
47. Zimina EP, Bruckner-Tuderman L and Franzke CW: Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment. J Biol Chem 280: 34019-34024, 2005.
48. Rizvi NA, Humphrey JS, Ness EA, et al: A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10: 1963-1970, 2004.
49. Tepel J, Dagvadorj O, Kapischke M, et al: Significant growth inhibition of orthotopic pancreatic ductal adenocarcinoma by CpG oligonucleotides in immunodeficient mice. Int J Colorectal Dis 21: 365-372, 2006.
50. Tepel J, Match C, Ketterer T, et al: A modified random oligonucleotide-based combination therapy for adjuvant treatment of pancreatic ductal adenocarcinoma. Int J Oncol 28: 1105-1112, 2006.